Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | CTSS | P25774 | 5/20 | 0.59 |
| ▸ | CTSL | P07711 | 5/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | KYNU | Q16719 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643831 | 1.00 | CTSK (0.60) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL1643830 | 1.00 | CTSK (0.60) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL4387860 | 0.91 | CTSK (0.64) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL527103 | 0.91 | CTSK (0.64) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL527104 | 0.91 | CTSK (0.64) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL10997126 | 0.91 | CASP1 (0.56) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4393193 | 0.90 | ITGB3 (0.52) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL4462027 | 0.89 | PPARA (0.55) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL18277716 | 0.89 | CTSK (0.57) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL22637150 | 0.89 | KYNU (0.57) | CTSKCTSSCTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530297-A | Ketone amide compound, preparation method and application thereof | 四川大学 | 2024-08-23 | — | — | CN | disclosed |
| EP-3144295-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | Divi's Laboratories Limited (IN) | 2017-03-22 | — | — | EP | disclosed |
| US-9447024-B1 | Process for the preparation of lacosamide | DIVI'S LABORATORIES LIMITED (IN) | 2016-09-20 | — | — | US | disclosed |
| US-9447024-B1 | Process for the preparation of lacosamide | DIVI'S LABORATORIES LIMITED (IN) | 2016-09-20 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-8933065-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-01-13 | — | — | US | disclosed |
| US-8829226-B2 | Lacosamide intermediate compound, preparation method thereof and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2014-09-09 | — | — | US | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| US-20110319649-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | EUTICALS GMBH (DE) | 2011-12-29 | — | — | US | disclosed |
| EP-2399901-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | Archimica GmbH (DE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2009145816-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7297706-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | WILEY MICHAEL R | 2007-03-29 | — | — | US | disclosed |
| US-7078415-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1455787-B1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | LILLY CO ELI (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1455787-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003049735-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | F2, F11, SERPINC1 | CTSK 3754/4885CTSS 4083/4885CTSL 3420/4885 |
| US-20110319649-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | NAAA, MEP1B, BCHE | CTSK 1129/4885CTSS 809/4885CTSL 1047/4885 |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | F2, F11, F12 | CTSK 4056/4885CTSS 4251/4885CTSL 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.